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Abstract
Background: Non-steroidal anti-inflammatory drugs such as indomethacin are widely used to treat inflammatory
diseases and manage pain, fever and inflammation in several conditions, including neuropsychiatric disorders.
Although they predominantly function by inhibiting cyclooxygenase (COX) activity, important COX-independent
actions also occur. These actions could be responsible for the adverse side effects associated with chronic and/or
high dose usage of this popular drug class.
Results: We examined gene regulation in the hippocampus after peripheral administration of indomethacin by
employing a microarray approach. Secondary confirmation and the brain expression pattern of regulated genes was
examined by in situ hybridization and immunohistochemistry. Transglutaminase 2, serum glucocorticoid inducible
kinase, Inhibitor of NF-kappa B and vascular endothelial growth factor were among genes that were prominently
upregulated, while G-protein coupled receptor 56 and neuropeptide Y were among genes that were downregulated
by indomethacin. Co-localization studies using blood vessel markers revealed that transglutaminase 2 was induced
specifically in brain vasculature.
Conclusions: The data demonstrate that COX-inhibitors can differentially regulate gene transcription in multiple,
functionally distinctly cell types in the brain. The results provide additional insight into the molecular actions of
COX-inhibitors and indicate that their effects on vasculature could influence cerebral blood flow mechanisms.
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Introduction
Pharmacological inhibitors of cyclooxygenases (COX),
non-steroidal anti-inflammatory drugs (NSAIDs), have
been widely used for several decades as anti-pyretics, anti-
inflammatory agents and analgesics. They function by
inhibiting the COX enzymes, COX-1 and/or COX-2
which are responsible for the production of prostaglandins
and mediating inflammation. As inflammation has been
implicated in the etiology of several neurodegenerative
illnesses it supports the testing of NSAIDs for neuropro-
tective and therapeutic effects [1, 2]. However, the results
of large scale clinical testing in Alzheimer’s disease
patients have indicated that contrary to the expectations
NSAIDs had an adverse rather than a beneficial effect [3].
Furthermore, clinical studies have shown that NSAID use
is associated with a higher risk for stroke [4]. Large scale
studies of NSAID use by healthy individuals have uncov-
ered significantly elevated incidence of cardiovascular
events and stroke [5].
Prostaglandin synthesis is known to drive the expression
of growth factors such as basic fibroblast growth factor
(bFGF) and vascular endothelial growth factor (VEGF),
molecules that play key roles in angiogenesis [6]. NSAIDs
are therefore prescribed in the treatment of cancer [7] for
their anti-angiogenic and anti-proliferative effects with the
intention of suppressing tumors by depriving them of vas-
cular support and inhibiting cell proliferation [8]. Despite
the wide therapeutic applications of NSAIDs, the risk of
cardiovascular and cerebrovascular effects has led to ele-
vated caution in their use [9]. Employing transgenic recep-
tor knockout mice, the notably higher cardiovascular risk
associated with highly selective COX-2 inhibitors was at-
tributed to their specific inhibition of prostacyclin, a vaso-
dilator, but allowing COX-1 mediated thromboxane A2, a
vasoconstrictor, to produce unopposed prothrombotic ef-
fects [10]. However, detailed meta-analysis of randomized
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human trial data found the incidence of cardiovascular
events in the use of COX-2 specific inhibitors to be similar
to that of conventional NSAIDs [11]. It is also not under-
stood how peripherally administered NSAIDs influence
the risk of vascular complications in the brain.
To obtain insight on the molecular actions of a non-
selective NSAID on the brain we tested indomethacin,
which inhibits both COX-1 and COX-2. We examined
gene expression changes in the hippocampus using a fo-
cused microarray after peripheral administration in rats.
Gene expression changes were independently validated
by quantitative PCR, in situ hybridization and immuno-
histochemical analysis. Indomethacin induced regulation




Employing a focused microarray that included 3000
genes representing trophic factor signaling and tran-
scription factor genes we examined the gene profile of a
non-selective Cox inhibitor, indomethacin, in the adult
rat brain. Peripheral administration was sufficient to
alter gene regulation in the hippocampus. Indomethacin
increased the expression of 14 genes and decreased the
expression of 6 genes (Table 1). Six genes were robustly
induced, exhibiting an upregulation higher than 2-fold.
In situ hybridization analysis showed that gene expression
changes were not limited to the hippocampus as several
genes, NPY, SGK, TGM2 and VEGF were also regulated
in the cortex (Figs. 1, 2). Cox-2 mRNA was downregulated
specifically in the dentate gyrus, CA1 and CA3 layers and
did not change in the cortex (Fig. 1a). NPY, which exhib-
ited a punctate expression pattern, decreased in all the re-
gions of the hippocampus and also the inner and outer
cortical layers (Fig. 1b). Serum glucocorticoid-inducible
kinase (SGK) was strikingly elevated in white matter re-
gions and only mildly elevated in the cortex. Increase in
hippocampal SGK was limited to the stratum lacunosum
moleculare (SLM) and hilus (Fig. 1c).
Transglutaminase 2 (TGM2) was expressed at low levels
in the brain of vehicle treated rats (Fig. 2a). Although
TGM2 was strongly induced by indomethacin the some-
what punctate and “hot spot” expression pattern did not
appear restricted to the hippocampus. Cortical induction
suggested high levels of expression in blood vessels (Fig. 2a).
Table 1 List of indomethacin regulated genes in the rat hippocampus is shown with corresponding GenBank accession number,
fold regulation and P-value
Gene name Accession number Fold regulation P-value
UPREGULATED GENES
Metallothionein 2 NM 001137564.1 3.12 0.001
Serum glucocorticoid inducible kinase NM 019232.3 3.07 0.017
Transglutaminase 2 NM 019386.2 2.79 9.05E-07
NF-kappa-B inhibitor alpha NM 001105720.2 2.77 0.003
S100A9-S100 calcium binding protein A9 NM 053587.1 2.76 0.002
SIN3A-SIN3 transcription regulator A NM 001108761.1 2.74 7.53E-06
Y box binding protein 3 NM 031979.3 1.98 2.68E-06
VEGF NM 031836.3 1.92 0.025
Numbl NM 001033888.1 1.85 0.016
Prefoldin 4 XM 003749636.2 1.84 3.93E-04
FGF2 NM 019305.2 1.72 0.006
MKP1-MAP kinase phosphatase 1 AF357203.1 1.63 0.004
Endothelial Nitric oxide synthase 3 CAB 77547.1 1.61 0.002
Hes 1-hes family bHLH transcription factor 1 NM 024360.3 1.59 0.001
DOWNREGULATED GENES
Zbtb20-zinc finger and BTB domain 20 NM 001105880.1 0.37 0.011
G-protein coupled receptor 56 NM 152242.2 0.55 0.001
Milk fat globule EGF-8 NM 012811.3 0.59 0.005
FGF9 D14839.1 0.62 0.033
Squalene synthase M95591.1 0.64 0.005
Neuropeptide Y NM 012614.2 0.67 0.01
Data are from N = 4 and P < 0.05
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Emulsion autoradiography provided additional support to
vascular expression of TGM2 as emulsion grain density
revealed a vascular pattern. Furthermore, quantitative PCR
analysis of isolated cortical vessels showed a 10-fold higher
expression in indomethacin treated rats compared to con-
trols (Fig. 2b).
In situ hybridization analysis of vascular endothelial
growth factor (VEGF) did not reveal any clearly discernible
elevation in mRNA (Fig. 2c). However, quantitative PCR
demonstrated a 3-fold upregulation of VEGF (Fig. 2d),
which was higher than the 1.9 fold regulation indicated by
the array experiments (Table 1). We therefore performed
emulsion autoradiography to obtain cell-level resolution
of VEGF expression. As shown in the two bottom panel
images of Fig. 2c (lower magnification at left and higher
magnification on the right) VEGF was highly induced in
particular cells in the hilus. Cells in the dentate gyrus did
not exhibit this high level of VEGF expression. ELISA
Immunoassay analysis of VEGF protein reflected the
mRNA regulation observed in the hippocampus (Fig. 2e).
It is interesting to note that in contrast to VEGF elevation
in the hippocampus, indomethacin decreased VEGF in
Fig. 1 In situ hybridization analysis of indomethacin-induced gene regulation. Representative photomicrographs of hippocampal sections hybridized
with radiolabeled riboprobes. Quantified expression of the indicated layers is shown by bar graphs on the right. Results are expressed as optical density
values relative to vehicle treatment and are the mean ± SEM of four separate animals, each analyzed in duplicate brain sections. a Downregulation of
Cox-2 is prominently seen in the hippocampus but not the cortex. Hippocampal cell layers are identified in the lower panel, showing reduction in the
dentate gyrus (DG), CA1 and CA3 regions. b NPY downregulation is evident in all the brain regions examined, hippocampus and cortex. Expression in
the inner and outer cortical layers were quantitate using boxes. c Marked SGK upregulation is seen in the white matter corpus callosum (CC) and lower
levels of induction in the stratum lacunosum moleculare (SLM), hilus and cortex
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the plasma (Fig. 2e), albeit at lower levels. Array analysis
indicated a modest upregulation in eNOS mRNA. eNOS
expression was therefore examined using immunohisto-
chemistry (Fig. 3). Expression appeared to be in the vascu-
lature and astrocytic processes, but eNOS protein did not
show appreciable indomethacin-induced upregulation that
was observed at the mRNA level.
TGM2 expression and cellular colocalization
Astrocytic expression of TGM2 protein was examined in
the hippocampus using glial fibrillary acidic protein
(GFAP) as the marker (Fig. 4). Although TGM2 was
expressed close to astrocytic processes, no colocalization
was observed, suggesting that astrocytes are not a site of
TGM2 production. Immunohistochemical analysis showed
Fig. 2 Regulation of TGM2 and VEGF. a In situ hybridization (left and middle panel) and emulsion autoradiography (right panel) photomicrographs of
TGM2 induction are shown in hippocampal section. The hippocampus is shown at higher magnification in the lower panels. Striking induction in
TGM2 is seen in multiple brain regions, including the choroid plexus (CP) after indomethacin administration. Emulsion autoradiographs are
representative images from indomethacin treated brains. The vascular expression pattern is indicated by the colored arrows. b TGM2 induction in
isolated cortical blood vessels was measured by QPCR. Bar graphs represent the mean from 3 animals, error bars are SEM (p < 0.05). c VEGF expression
in vehicle and indomethacin treated animals is shown in the top panel. Cresyl violet stained emulsion autoradiographs of vehicle and indomethacin
treated animals is shown in the middle panel. The boxed region in the indomethacin treated section is shown at two levels of magnification in the
bottom panel. d VEGF induction in the hippocampus was examined by QPCR. Bar graphs represent the mean from 3 animals, error bars are SEM
(p < 0.05). e ELISA analysis of VEGF protein levels in the hippocampus and plasma. VEGF in indomethacin treated animals are shown as a percentage
of vehicle VEGF levels. Bar graphs represent the mean from 4 animals, error bars are SEM (p < 0.05)
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that TGM2 was expressed at low levels in dentate gyrus
neurons (Fig. 4) and that the indomethacin-induced upreg-
ulation was mainly in the vasculature (Fig. 5a). Blood ves-
sels were identified by staining with fluorescently labeled
tomato lectin. TGM2 expression in blood vessels was not
uniform and exhibited punctate regions of high expression.
We also noted that the highest levels of TGM2 expression
and indomethacin-induced elevation was in larger vessels
(>10 μm in diameter). Neuronal TGM2 expression was
comparable in both indomethacin and control groups.
Strong induction of TGM2 occurred in the choroid plexus
and appeared specific to CP blood vessels and not the epi-
thelial cells (Fig. 5b). To obtain further insight into the
vascular expression of TGM2 we performed immunohisto-
chemical analysis using additional cell type markers (Fig. 6).
Rat endothelial cell antigen (RECA), a widely used marker
of endothelial cells, revealed substantial colocalization with
TGM2 (Fig. 6a). However, grains representing high levels
of TGM2 appeared to be extracellular. We tested the role
of the basement membrane by utilizing collagen IV as a
specific marker. Although collagen IV yielded a clear vas-
cular pattern, its expression did not colocalize with TGM2
(Fig. 6c). Von willebrand factor staining colocalized with
TGM2 and provided evidence that endothelial cells are the
likely source of indomethacin-induced vascular upregula-
tion (Fig. 6d).
Cox2 specific inhibitor induces vascular TGM2
As indomethacin is a nonselective inhibitor of cyclo-
oxygenase we investigated a selective COX-2 inhibitor,
celecoxib, for its ability to regulate TGM2 expression.
Celecoxib strongly induced TGM2 in cerebral blood vessels
Fig. 3 Immunohistochemical analysis of eNOS expression in the brain. a eNOS expression in the hippocampal CA1 and molecular layer (ML) is
shown after indomethacin and vehicle administration. b eNOS expression in the dentate gyrus cell layer is shown after indomethacin and
vehicle administration
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(Fig. 7). The expression pattern of Celecoxib-induced
TGM2 was similar to indomethacin, larger cortical
vessels. Double immunohistochemical analysis with
GFAP showed that, like indomethacin-induced TGM2,
celecoxib-induced TGM2 was also not expressed in
GFAP-positive astrocytes. Overall, the level of TGM2
induction appeared to be higher with celecoxib ad-
ministration in comparison to the indomethacin in-
duced elevation.
Discussion
We conducted a gene expression analysis in rat brain
tissue after peripheral NSAID administration. Although
our focus was the hippocampus, subsequent secondary
validation was performed using in situ hybridization and
immunohistochemical analyses, yielding regional and
cellular insight.
NSAIDs are considered safe medications and therefore
highly used worldwide to treat a variety of pain and in-
flammation conditions. They are also used long term at
high doses as antitumor agents [12]. As several NSAIDs
are available over-the-counter, the potential for chronic
usage or in large doses is particularly high. While the
predominant mechanism attributed to their actions is
the inhibition of prostaglandin synthesis, NSAIDs have
also been shown to produce a spectrum of useful effects
that are cyclooxygenase and prostaglandin-independent
[13]. For example, the ability to inhibit angiogenesis has
attractive clinical applications in cancer treatment [14],
but require doses that are several fold higher than those
used to inhibit prostaglandins [13]. These antitumori-
genic and antiangiogenic doses have been demonstrated
to directly alter gene expression in different cell types
[15, 16], suggesting that NSAIDs possess multiple modes
of action.
Our brain gene expression study revealed several tar-
get genes that have not been previously associated with
NSAID treatment. While NSAID induced metallothio-
nein gene regulation has been previously reported in the
liver, our array experiments show that it produces a
similar increase in the hippocampus. Metallothionein
induction in the brain has been implicated in neuronal
repair mechanisms and occurs as a protective response
to injury and inflammation [17]. They are secreted by
reactive astrocytes and modulate intracellular actions via
the neuronal megalin receptor. Elevating brain MT
levels via NSAID administration can protect against
neuroinflammation and also elevate trophic factors such
as erythropoietin which has wide spectrum neuroprotec-
tive effects. Serum and glucocorticoid-inducible kinase
Fig. 4 Astrocytic localization of indomethacin-induced TGM2. Colocalization analysis of GFAP and TGM2 in the hippocampal cell layers is shown. Merged
images combining GFAP, TGM2 and nuclear DAPI staining is shown in the right-most panel. HL- hilus, ML- molecular layer, DG – dentate gyrus
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(SGK) is induced in the brain primarily by glucocorti-
coids [18], but also by several different stimuli and
stressors, including fear conditioning, enriched environ-
ment, plus maze exposure, cell volume and drugs of abuse
[19]. However, our in situ hybridization analysis shows
that the highest levels of regulation are in white matter
regions. This could be in response to indomethacin-
induced reduction in blood flow. SGK is induced in the
hippocampus and corpus callosum after transient global
ischemia [20] and serves to protect against apoptosis by
activating PI3K/Akt signaling. The high sensitivity of
white matter to ischemia is well known [21] and the
accompanying cell volume changes could be the likely
trigger for SGK upregulation as an alteration in cell
volume is a strong stimulus for its induction [19].
The topic of indomethacin-induced ischemia has been
controversial as human imaging studies have demon-
strated the known vasoconstrictor effects of indometh-
acin [22] but no ischemic regions were observed [23].
Studies in pigs [24] and baboons [25] have shown
marked decreases in cerebral blood flow, lowering it by
30 % in these species. The possibility of microvascular
ischemia has not been sufficiently explored and could be
challenging for live imaging analysis as it would require
capillary level resolution. The robust vascular induction of
transglutaminase 2 (TGM2) is perhaps the most interesting
Fig. 5 Immunohistochemical analysis of TGM2 induction in the brain. a TGM2 expression in the discrete cortical blood vessels is shown.
Fluorescent-tagged tomato lectin was used a blood vessel marker and DAPI was used to label nuclei. Indomethacin treated sections are in the
top row and vehicle treated in the bottom row. Merged images of all 3 channels are in the right-most panel. b Strong TGM2 expression is shown
in the lateral choroid plexus. Indomethacin treated sections are in the top row and vehicle treated in the bottom row. Merged images of all 3
channels are in the right-most panel
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outcome of this study. TGM2 is a multifunctional, scaffold-
ing, calcium-dependent enzyme that is expressed at low
levels in the brain but is strongly induced after stroke injury
[26, 27]. TGM2 overexpression increases cell death while
inhibitors and gene deletion produce beneficial effects [27,
28]. However, it appears that cellular phenotype is a critical
factor as TGM2 deletion in neurons renders them vulner-
able to ischemic stress while ablation in astrocytes is pro-
tective [28]. Our co-localization experiments indicate that
TGM2 induction occurs in endothelial cells and not in
neurons or astrocytes.
Secreted protein TGM2 can act on cells in the vicinity
to elicit diverse functions. It is sharply elevated by vaso-
constriction and plays a central role in the inward re-
modeling of small arteries following a reduction in blood
flow [29]. Blood vessels are held in the constricted state by
a specific TGM2 activity that cross-links several extracel-
lular matrix proteins such as collagen, fibronectin and
Fig. 6 Co-localization analysis of indomethacin induced TGM2 expression in cortex blood vessels. a TGM2 expression in endothelial cells is shown
using rat endothelial cell antigen (RECA) as an endothelial marker. b Using GFAP as an astrocytic marker shows that TGM2 is not expressed in
GFAP-positive astrocytes. c TGM2 does not co-localize with Collagen IV which was used as basement membrane marker. d TGM2 expression in
endothelial cells is shown using Von willebrand factor (vWF) as an additional endothelial marker
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vitronectin, resulting in lasting vascular entrenchment and
reduced diameter [30, 31]. The array data indicated a
modest induction in eNOS. This is intriguing as eNOS is
known to inhibit the crosslinking activity of TGM2 via
nitric oxide mediated S-nitrosylation [32]. eNOS could
also produce vasodilation to counter some of the vasocon-
strictive actions of TGM2. However, we were unable to
detect eNOS induction at the protein level. It is likely that
the mild induction of eNOS mRNA does not result in
detectable levels of eNOS protein elevation. The upregula-
tion of TGM2 in the choroid plexus (CP) could influence
CSF secretion. Blood flow in the CP is 3 times faster than
other brain regions [33] in order to facilitate its secretory
functions. The CP plays important roles in brain homeo-
stasis and function [34, 35]. If TGM2 constricts CP capil-
laries and reduces blood flow it is likely to negatively
impact CSF production and overall CP function.
Indomethacin is clinically effective in decreasing ele-
vated intracranial pressure caused by head injury, and is
mediated by decreasing cerebral blood flow [36]. The
molecular mechanism involved in this action is not cur-
rently understood. Our data indicate that TGM2 could be
involved in the vascular effects of indomethacin. As both
celecoxib and indomethacin similarly induced TGM2 it is
likely that it is a consequence of their ability to modulate
gene transcription rather than COX inhibition. Alter-
nately, it could be related to COX-2 inhibition as both
indomethacin and celecoxib suppress COX-2. It is inter-
esting to note the downregulation of GPR56, an atypical
G-protein coupled receptor that binds TGM2 and antago-
nizes its activity [37]. In the brain, GPR56 is abundantly
expressed in the endfeet of radial glia and regulates base-
ment membrane integrity [38].
The differential effects on VEGF levels in plasma versus
the hippocampus is intriguing. The lowering of plasma
VEGF was expected due to the known anti-angiogenic
activity of NSAIDs, but the brain upregulation appears
paradoxical. A previous indomethacin study reported a
hypoxia-induced elevation of VEGF and FGF2 in the renal
cortex [39]. The increase in hippocampal VEGF could be
due to localized hypoxia that is detected by particular
astrocytic cells that respond by upregulating VEGF mRNA
[40]. NF-kappa B (NF-κB) is an inducible transcription
factor that serves as a key mediator of inflammation by
regulating the expression of several downstream pro-
inflammatory genes. NSAIDs, particularly salicylates such
as Aspirin, are known to inhibit NF-κB and do so by sup-
pressing the degradation of its inhibitor, IκBα, via inactiva-
tion of the kinase IKK [41]. The induction of IκBα gene
expression that we observed appears to be an additional
transcriptional mechanism for inhibiting NF-κB.
The downregulation of Neuropeptide Y (NPY) in the
cortex and hippocampus by indomethacin could have
negative behavioral consequences under stressful condi-
tions as the NPY system plays an important role in
countering the adverse emotional and behavioral effects
of stress [42–44]. NPY is induced in the hippocampus
by antidepressant treatment [45, 46] and independently
produces antidepressant [47] and anxiolytic [48] effects.
Although adverse behavioral consequences associated
with NSAID use are rare, indomethacin and selective
COX-2 inhibitors have been reported to exacerbate
symptoms in patients suffering from psychiatric illnesses
[49]. This gene expression study sheds light on the po-
tential CNS effects of NSAIDs and also provides an ex-
planation for some of their observed vascular actions. As
Fig. 7 Celebrex-induced TGM2 expression in cortical blood vessels is shown. Low levels are detectable in vehicle treated animals. Expression does
not co-localize with GFAP-positive astrocytes and appear to be in endothelial cells. Merged images combining TGM2 and GFAP channels are in
the right panel
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NSAIDs constitute 5–10 % of all drug prescriptions and
are frequently used chronically, future studies should
focus on lower dose but longer treatment regimens and
also seek to clarify the cyclooxygenase-dependent and
independent effects.
Conclusions
In summary, we conclude that COX inhibitors elicit
gene expression changes in the brain and produce differ-
ential cell-type specific effects by acting on neuronal and
vascular cells. The elevation in vascular TGM2 could
potentially impact cerebrovascular tone and blood flow.
Our results provide new insight into the molecular ac-
tions of COX inhibitors and their ability to influence
gene transcription in the hippocampus.
Methods
Animals and treatment
Male SD rats (weighing 250–275 g) were pair-housed and
maintained in standard conditions with a 12-h light/dark
cycle and ad libitum access to food and water. All animal
use procedures were in strict accordance with the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals and were approved by the Animal
Care and Use Committee. Indomethacin, Celecoxib
(Cayman Chemical Company) or vehicle (10 % DMSO in
phosphate buffered saline) was injected (10 mg/kg, i.p.)
once daily for three days. Animals were sacrificed 7 h after
their last injection. The hippocampus was dissected, rap-
idly frozen on dry ice and kept at −80 °C until used. Trunk
blood was collected into vacutainer tubes containing
sodium heparin (BD Biosciences). Blood was centrifuged
at 1000 × G for 15 min at 4 °C. Plasma aliquots were
stored at −80 °C prior to use.
Protein detection
Hippocampus and plasma levels of VEGF (R&D Systems)
protein were assessed by ELISA kit according to manufac-
turer’s instructions. Whole hippocampus was homoge-
nized in 0.5 ml buffer (137 mM NaCl, 20 mM Tris–HCl
(pH 8.0), 1 % NP40, 10 % glycerol) and 50 μl of homogen-
ate was used for each assay. Samples were run in dupli-
cate. Total protein concentration was determined by BCA
assay according to manufacturer’s instructions (Pierce
Biotechnology, Inc., Rockford, IL).
Microarray analysis of gene expression
Array analysis was performed using a focused microarray
platform [50]. The hippocampus was manually dissected
and quickly frozen on dry ice. RNA was isolated using a
non-phenolic procedure (RNAqueous kit, Ambion). RNA
yields were quantitated by Nanodrop spectrophotometer
(Thermo Scientific) and quality was verified by gel electro-
phoresis or real time PCR. 3ug of hippocampal RNA
was reverse transcribed into cDNA using oligo dT primers
and indirectly labeled using fluorescent dendrimers
(Genisphere, Hatfield, PA). A two-step hybridization and
labeling protocol was used where the chip was hybridized
to cDNA overnight, washed and post-stained with fluores-
cent dendrimers. Slides were scanned using a GenePix
scanner (Molecular Devices, Sunnyvale, CA). Image ana-
lysis was performed using GenePix Pro software. Resulting
files were imported into GeneSpring (Agilent Technolo-
gies, Santa Clara, CA) for additional visualization and data
mining. A gene was considered as being expressed if its
signal intensity was a minimum of twice the background
in 3 of the 4 replicates. Per-chip normalization was per-
formed by dividing the expressed genes by the median of
two housekeeping control genes that were not regulated,
b-tubulin and cyclophilin. Gene regulation was deter-
mined by taking the log ratio of the median experimental
channel signal to the median control channel signal. Up-
regulated genes were defined as having an average expres-
sion ration of >1.3, and the downregulated genes were
defined as having an average expression ratio of <0.7.
These values were determined by performing homotypic
hybridizations where the same sample was hybridized in
both channels (cy3 and cy5).
Statistical analysis
Analysis of microarray data was performed by an unpaired
t test using the cross-gene pooled error method in Gene-
spring software. Relative gene expression using quantita-
tive PCR was calculated using the ΔΔCt method and
analyzed using the t test in GraphPad software. In situ
hybridization images were quantified using NIH Image
software, and statistical analysis (t-test) was performed
using Microsoft Excel Analysis tool Pak.
In situ hybridization and emulsion autoradiography
ISH was performed using radiolabeled riboprobes accord-
ing to conventional protocols with minor modifications
[51]. Riboprobes were generated by PCR amplification
using gene-specific primers, Cox2 - CGCTGCTGCCGGA
CACCTTC, CCACCAGCAGGGCGGGATAC; VEGF –
TGCCCACGTCGGAGAGCAAC, CTCAAGCTGCCTC
GCCTTGC. The reverse primer included a T7 template
sequence (TAATACGACTCACTATAGGGAGA) on the
5′end. Whole rat brain cDNA was used as the template
for PCR, which was performed in a real-time PCR instru-
ment using the Quantitect Sybr Green PCR kit (Qiagen).
PCR product was purified by ethanol precipitation and re-
suspended in TE buffer. One microgram of the 300–400 bp
PCR product was used to produce radiolabeled riboprobe
using a T7-based in vitro transcription kit (Megashortscript;
Ambion, Austin, TX, USA). All riboprobes were verified by
sequencing of the PCR product.
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Real-time PCR analysis
Gene specific primers for TGM2, VEGF, FGF2, NFKBIA,
SGK, S100A9 were designed using “Primer 3” web-based
software. Amplification parameters were 15 min at 95 °C
(to activate hotstart Taq polymerase) and then 94 °C 2 s,
60 °C 30 s and 72 °C 30 s. PCR quantitation was per-
formed by converting differences in Ct (cycle threshold)
values to fold regulation after normalizing to the un-
regulated housekeeping gene, cyclophilin. Blood vessels
were manually isolated from the outer surface of the
brain and placed in eppendorf tubes that were then fro-
zen on dry ice. Blood vessel isolation was performed
with care to minimize any inclusion of surrounding
neural tissue. RNA from blood vessel and hippocampus
tissue were used to make cDNA for comparison of tran-
script levels of TGM2 in both tissue types.
Immunohistochemistry
Immunohistochemical studies were performed using cryo-
cut coronal sections (16 μm). Sections were fixed in Histo-
choice fixative (Sigma) or cold 4 % formalin for 10 min
followed by a 5 min wash in cold 1x PBS. All incubations
were performed on the slide by encircling sections with an
ImmEdge pen (Vector Laboratories, Burlingame, CA,
USA), then adding antibody solution directly to the sec-
tions. Sections were blocked with 5.0 % BSA (w/v) in PBS
(Molecular biology grade lyophilized bovine serum albu-
min, Sigma) at 4 °C for 30 min. Sections were incubated
with different primary antibody combinations in antibody
solution (2.5 % BSA in PBS) at 4 °C overnight (TGM2,
1:150, Cell Signaling (Beverly, MA, USA); Lectin-Dylight
594 (1:500, Vector Laboratories, Burlingame, CA, USA);
RECA (1:50, Serotec (Oxford, UK); GFAP (1:1000), Colla-
gen IV (1:100, Abcam, Cambridge, MA, USA), eNOS
(1:300, Abcam). Following primary antibody incubation,
slides were washed in 1xPBS three times for 5 min each at
room temperature. Slides were then incubated in appro-
priate fluorescent secondary antibody (1:500, Alexa-488
and 594, Life Technologies) in 2.5 % BSA in PBS for 2 h at
room temperature. The slides were then rinsed in 1x PBS
three times for five minutes each and coverslipped using
VectaMount (Vector Labs). Sections were viewed and
images were captured using a Nikon Eclipse Ni micro-
scope equipped with DS-Qi1 monochrome, cooled digital
camera and NIS-AR 4.20 Elements imaging software.
Indomethacin, and vehicle treated sections were captured
using identical exposure settings.
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